Journal Article

Treatment of HCV liver disease by recombinant interferon α

F. Bailly, N. Si, A. Si and C. Trepo

in Nephrology Dialysis Transplantation

Volume 11, issue supp4, pages 56-57
Published in print January 1996 | ISSN: 0931-0509
Published online January 1996 | e-ISSN: 1460-2385 | DOI:
Treatment of HCV liver disease by recombinant interferon α

Show Summary Details


Interferon α has confirmed its efficacy for the therapy of chronic hepatitis C. Half of the patients treated will normalize their plasma ALT at the end of a 6-month course of 3 MU thrice a week. This biochemical response is associated with a reduction of HCV RNA (viraemia) from serum and with significant improvement of liver histology. Despite those beneficial effects, 50% of treatment responders generally relapse after treatment arrest. Increasing doses to 6 MU and/or the duration of interferon therapy increases the proportion of long-term sustained responders. Combining therapy with ribavirin, a nucleoside analogue, also appears to have a similar effect.

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.